Additionally, CD133 expression is elevated in OSCC and associated with increased resistance; targeting CD133 combined with cisplatin treatment effectively inhibits OCSC-driven OSCC initiation [23]. This evidence concerns the gene PROM1 and oral cavity squamous cell carcinoma.